# An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

> **NCT03650413** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** UTTR1147A

## Key facts

- **NCT ID:** NCT03650413
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-14
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 143 (ACTUAL)
- **Why stopped:** This study was terminated early by the Sponsor based on the interim analysis of Study GA39925 (NCT03558152) that showed low efficacy of UTTR1147A in ulcerative colitis. Development of the drug in this indication has been terminated.
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650413, "An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03650413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*